Related references
Note: Only part of the references are listed.The ABCG5/8 Cholesterol Transporter and Myocardial Infarction Versus Gallstone Disease
Stefan Stender et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Liver-specific induction of Abcg5 and Abcg8 stimulates reverse cholesterol transport in response to ezetimibe treatment
Jessica B. Altemus et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Nathan O. Stitziel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Anette Varbo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Discovery and refinement of loci associated with lipid levels
Cristen J. Willer et al.
NATURE GENETICS (2013)
Extreme Bilirubin Levels as a Causal Risk Factor for Symptomatic Gallstone Disease
Stefan Stender et al.
JAMA INTERNAL MEDICINE (2013)
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis
Brian A. Ference et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Trine Holm Johannsen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
New pathophysiological concepts underlying pathogenesis of pigment gallstones
Libor Vitek et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2012)
Sterol Transporter Adenosine Triphosphate-Binding Cassette Transporter G8, Gallstones, and Biliary Cancer in 62,000 Individuals from the General Population
Stefan Stender et al.
HEPATOLOGY (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly
Eliana Polisecki et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses
Marianne Benn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia
B. Martin et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Statin Use and the Risk of Cholecystectomy in Women
Chung-Jyi Tsai et al.
GASTROENTEROLOGY (2009)
Statin Use and Risk of Gallstone Disease Followed by Cholecystectomy
Michael Bodmer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
The g.-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels
Chun-Wu Chen et al.
JOURNAL OF HUMAN GENETICS (2009)
Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Allen J. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
Christopher P. Cannon et al.
AMERICAN HEART JOURNAL (2008)
Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones
Helen H. Wang et al.
GASTROENTEROLOGY (2008)
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes
Jerome L. Fleg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Ezetimibe prevents cholesterol gallstone formation in mice
Silvia Zuniga et al.
LIVER INTERNATIONAL (2008)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
Anne B. Rossebo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Simvastatin with or without ezetimibe in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Debbie A. Lawlor et al.
STATISTICS IN MEDICINE (2008)
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetirnibe
Ryan E. Temel et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2
Waddah A. Alrefai et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Cholesterol gallstone disease
Piero Portincasa et al.
LANCET (2006)
The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1)
M Garcia-Calvo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption
SW Altmann et al.
SCIENCE (2004)
ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion
GA Graf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia
RH Knopp et al.
EUROPEAN HEART JOURNAL (2003)
Share Paper
